{
  "symbol": "BEIGF",
  "year": 2024,
  "competition_summary": [
    {
      "competitor": "NMPA",
      "mentions": 3,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Amgen",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Luye",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "BeiGene",
      "mentions": 3,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "the United States Patent and Trademark Office",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "FDA",
      "mentions": 7,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "the Amended PRC Patent Law",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "EU",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "BTK",
      "mentions": 2,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "IMBRUVICA",
      "mentions": 2,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "MCL",
      "mentions": 2,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "AstraZeneca\u2019s CALQUENCE \u00ae",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "CLL",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "SLL",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Lilly\u2019s JAYPIRCA",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Innocare",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "EMA",
      "mentions": 2,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Merck",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "BMS",
      "mentions": 2,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "OPDIVO \u00ae",
      "mentions": 2,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Roche",
      "mentions": 3,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "AstraZeneca\u2019s IMFINZI \u00ae",
      "mentions": 2,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Sanofi\u2019s",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "GSK\u2019s JEMPERLI \u00ae",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Junshi",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "KEYTRUDA \u00ae",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Innovent\u2019s TYVYT \u00ae",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Hengrui\u2019s AIRUIKA \u00ae",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Akeso\u2019s ANNIKE \u00ae",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Henlius\u2019s HANSIZHUANG \u00ae",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "CStone",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Hengrui",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Akeso",
      "mentions": 2,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "PD-L1",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "AstraZeneca",
      "mentions": 2,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "NDA",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Fluzoparib",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Hengrui/Hansoh",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "TIGIT",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Roche/Genentech",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "iTeos Therapeutics",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Bio-Thera",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Lupeng Pharmaceutical",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "TargetRx",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    },
    {
      "competitor": "Zentalis Pharmaceuticals",
      "mentions": 1,
      "context": "competition from generic medications for our medicines and any approved drug candidates even if we successfully obtain patent protection. The scope, validity or enforceability of our or our collaborators\u2019 patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any p"
    }
  ]
}